On 17 July 2013, orphan designation (EU/3/13/1157) was granted by the European Commission to Voisin Consulting SARL, France, for S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one for the treatment of follicular lymphoma.
The sponsorship was transferred to Abbvie Ltd, United Kingdom, in November 2015, then to Voisin Consulting S.A.R.L., France, in September 2016 and finally to Verastem Europe GmbH, Germany, in November 2019.
|Disease / condition||
Treatment of follicular lymphoma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
Verastem Europe GmbH
Lange Strasse 70
Lower Saxony 29664
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.